Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Admission Application & Exercise of Options

21 Mar 2023 07:00

RNS Number : 5850T
Cambridge Cognition Holdings PLC
21 March 2023
 

21 March 2023

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Admission Application

 

Exercise of Options and PDMR Dealing

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that an application has been made to the London Stock Exchange for a block admission of 1,000,000 ordinary shares of £0.01 each ("Ordinary Shares") to be admitted to trading on AIM ("Block Admission"). 

 

The Block Admission relates to Ordinary Shares that will be issued from time to time in accordance with the exercise of options previously granted by the Company. All Ordinary Shares issued pursuant to the Block Admission above will rank pari passu with the existing Ordinary Shares.

 

It is expected that the Block Admission will become effective on or around 23 March 2023.

 

In addition, the Company has issued and allotted 199,701 new Ordinary Shares in the share capital of the Company following the exercise of 222,820 options on 16 March 2023 ("Option Exercise"). Of the options exercised, 90,000 were exercised utilising the net cashless exercise feature, resulting in 23,119 options being surrendered to the Company. The options were exercised pursuant to the Cambridge Cognition Holdings 2013 EMI Share Option Plan. The new Ordinary Shares will be admitted to trading pursuant to the Block Admission.

 

Included in the exercise of options were options over 119,534 Ordinary Shares held by PDMRs of the Company as detailed in the table below:

 

Director/ PDMR

Position

Existing interest in Ordinary Shares

Number of Options over Ordinary Shares exercised

Resultant interest in Ordinary Shares

Rollover options remaining after exercise

Ricky Dolphin

Chief Technology Officer

-

119,534

119,534

-

 

 

Total voting rights

 

Following the issue of the new Ordinary Shares pursuant to the Option Exercise, the total number of voting rights of the Company will be 34,815,389. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

 

The Company intends to notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Cambridge Cognition Holdings Plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

Tel: 020 3903 7715 

 

 

IFC Advisory Ltd (Financial PR and IR) 

Tim Metcalfe / Graham Herring / Zach Cohen 

 

Tel: 020 3934 6630 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ricky Dolphin

2

Reason for the notification

a)

Position/status

Chief Technology Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

GB00B8DV9647

b)

Nature of the transaction

Exercise of Share Options

c)

Price(s) and volume(s)

   Price(s)

Volume(s)

a) £0.01

b) £0.70

c) £0.28

a) 19,721

b) 1,600

c) 98,213

d)

Aggregated information

- Aggregated volume

- Price

 

119,534

£0.24

e)

Date of the transaction

20 March 2023

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEPPUWAWUPWGMU
Date   Source Headline
27th Feb 20184:25 pmRNSHolding(s) in Company
10th Jan 20187:00 amRNSTrading Update and Notice of Results
5th Dec 20178:55 amRNSHolding(s) in Company
28th Nov 20177:00 amRNSWearable technology demonstrates high compliance
2nd Nov 20177:00 amRNSGrant of Options
10th Oct 201711:00 amRNSHolding(s) in Company
10th Oct 201710:58 amRNSHolding(s) in Company
6th Oct 20177:00 amRNSIssue of Equity
21st Sep 20177:00 amRNSHalf-year Report
12th Sep 20177:00 amRNSAward of Funding
31st Aug 20177:00 amRNSNotice of Results
12th Jun 20179:56 amRNSHolding(s) in Company
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
7th Jun 20177:00 amRNSSpeech recognition for clinical trials
25th May 20172:22 pmRNSResult of AGM & Board Change
24th May 20174:27 pmRNSHolding(s) in Company
22nd May 20177:00 amRNSIssue of Equity
11th May 20171:07 pmRNSHolding(s) in Company
10th May 20177:00 amRNSGrant of Options
2nd May 20177:00 amRNSPosting of Annual Report & Notice of AGM
30th Mar 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSAnnual Financial Report
16th Mar 20177:00 amRNSCANTAB used in EBBINGHAUS cognitive function trial
7th Mar 20177:00 amRNSLaunch of web-based testing for virtual research
24th Feb 20177:00 amRNSPartnership With Takeda For Wearables
23rd Feb 20177:00 amRNSNotice of Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUS regulatory clearance for CANTAB Mobile
4th Nov 20167:00 amRNSGrant of Options
13th Oct 20167:00 amRNSContract
29th Sep 20167:00 amRNSContract Win
22nd Sep 20167:00 amRNSHalf Yearly Report
20th Sep 20167:00 amRNSContract signed
25th Aug 20167:00 amRNSNotice of Results
18th Aug 201610:27 amRNSHolding(s) in Company
16th Aug 20167:00 amRNSCognition Kit Feasibility Study
20th Jul 20167:00 amRNSContract Win
24th Jun 201612:33 pmRNSResult of AGM
22nd Jun 20167:00 amRNSDistribution Agreement with MANUS Neurodynamica
2nd Jun 20167:00 amRNSDistribution Agreement with AnthroTronix
25th May 20162:00 pmRNSNotice of AGM & Posting of Annual Report
6th May 20167:00 amRNSDirector Dealing
5th May 20167:00 amRNSCANTAB Mobile - submission for FDA clearance
3rd May 20163:06 pmRNSHolding(s) in Company
25th Apr 20162:00 pmRNSDirector Dealing
25th Apr 20167:01 amRNSPlacing to raise £1.25m
25th Apr 20167:00 amRNSFinal Results
11th Apr 20167:00 amRNSCANTAB Recruit release
4th Apr 20167:00 amRNSPresentation of Prototype Wearable
30th Mar 20164:06 pmRNSAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.